Telo Therapeutics is developing a small molecule that is well positioned to become a best in class inhibitor of XPO1, a clinically validated but under-exploited oncology target. The only marketed XPO1 inhibitor, Selinexor, suffers from severe toxicities, limiting the clinical dose and restricting the ability to achieve efficacy in patients. Telo’s unique chemistry and distinct MoA leads to significantly improved tolerability in animals and dramatic tumor regressions across multiple cancer types including brain, liver, lung, bladder, and prostate. Telo Therapeutics is actively raising a $25M financing to advance their small molecule to IND and run a phase 1 trial.